HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Free Trial' Plus False Claims Equals More FTC Enforcement In Supplement Market

This article was originally published in The Rose Sheet

Executive Summary

FTC on consecutive days announced court order closing a California business allegedly charging consumers for products and enrolling them in negative-option continuity plans without their consent after they responded to bogus free trial online offers, and started mailing 16,596 checks totaling more than $750,000 to consumers who bought deceptively marketed supplements from a Maine firm that also lured customers with a free trial pitch.

Advertisement

Related Content

Health, Beauty And Wellness News: FTC, FDA Enforcement, Noosh In Vitamin Shoppe, GNC Tests Store Features
Health, Beauty And Wellness News: Warnings, Launches, Funds, Fines
Ad Firm Behind Bogus Weight Loss Claims Fined $2M: Health And Wellness Industry News
FTC Curbs Another 'Free' Ride: Health And Wellness Industry News
Industry News Roundup

Topics

Advertisement
UsernamePublicRestriction

Register

RS122550

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel